Susquehanna International Group
CAPR icon

Susquehanna International Group’s Capricor Therapeutics CAPR Stock Holding History

Susquehanna International Group’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.62M Sell
53,375
-24,232
-31% -$646K ﹤0.01% 6661
2025
Q4 		$2.24M Buy
77,607
+57,730
+290% +$754K ﹤0.01% 5418
2025
Q3 		$143K Sell
19,877
-26,138
-57% -$192K ﹤0.01% 11315
2025
Q2 		$457K Sell
46,015
-122,973
-73% -$1.3M ﹤0.01% 9385
2025
Q1 		$1.6M Sell
168,988
-112,314
-40% -$1.56M ﹤0.01% 6043
2024
Q4 		$3.88M Buy
281,302
+157,890
+128% +$2.77M ﹤0.01% 4002
2024
Q3 		$1.88M Buy
123,412
+82,915
+205% +$410K ﹤0.01% 5386
2024
Q2 		$193K Sell
40,497
-275,763
-87% -$1.54M ﹤0.01% 10410
2024
Q1 		$2.15M Buy
316,260
+167,145
+112% +$808K ﹤0.01% 5167
2023
Q4 		$729K Buy
149,115
+19,840
+15% +$64.6K ﹤0.01% 7765
2023
Q3 		$442K Buy
129,275
+80,640
+166% +$453K ﹤0.01% 8519
2023
Q2 		$232K Buy
48,635
+14,117
+41% +$62K ﹤0.01% 9974
2023
Q1 		$146K Sell
34,518
-94,552
-73% -$407K ﹤0.01% 10934
2022
Q4 		$498K Sell
129,070
-16,361
-11% -$78.1K ﹤0.01% 7887
2022
Q3 		$873K Sell
145,431
-24,206
-14% -$124K ﹤0.01% 6987
2022
Q2 		$592K Buy
169,637
+11,175
+7% +$39.7K ﹤0.01% 7846
2022
Q1 		$544K Sell
158,462
-56,139
-26% -$221K ﹤0.01% 8754
2021
Q4 		$629K Sell
214,601
-23,764
-10% -$83.3K ﹤0.01% 8539
2021
Q3 		$958K Sell
238,365
-42,580
-15% -$194K ﹤0.01% 7672
2021
Q2 		$1.44M Buy
280,945
+72,719
+35% +$308K ﹤0.01% 6757
2021
Q1 		$974K Buy
208,226
+26,473
+15% +$152K ﹤0.01% 7811
2020
Q4 		$623K Sell
181,753
-102,483
-36% -$444K ﹤0.01% 7805
2020
Q3 		$1.49M Buy
284,236
+165,414
+139% +$964K ﹤0.01% 5189
2020
Q2 		$547K Buy
+118,822
New +$518K ﹤0.01% 7182
2017
Q1 		– Sell
-1,432
Closed -$38K – 8983
2016
Q4 		$38K Buy
+1,432
New +$42.9K ﹤0.01% 9347
2016
Q1 		– Sell
-1,570
Closed -$48K – 9027
2015
Q4 		$48K Buy
+1,570
New +$62.5K ﹤0.01% 9106

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Susquehanna International Group's CAPR Position: Q1 2026 in Review

Susquehanna International Group reduced its Capricor Therapeutics (CAPR) stake by 31% in Q1 2026, selling an estimated $646K and leaving 53,375 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #6661.

Susquehanna International Group first reported a position in CAPR in Q4 2015 and has held it in 26 quarters since. The position peaked at $3.88M in Q4 2024. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Susquehanna International Group held 53,375 shares of Capricor Therapeutics worth $1.62M as of Q1 2026.
  • Susquehanna International Group sold 24,232 Capricor Therapeutics shares in Q1 2026, an estimated $646K.
  • Capricor Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6661 holding.
  • Susquehanna International Group first reported a position in Capricor Therapeutics in Q4 2015 and has held it in 26 quarters since.
  • Susquehanna International Group's Capricor Therapeutics position peaked at $3.88M in Q4 2024.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.